DNA icon

Pseudohypoaldosteronism Type I Panel

Summary and Pricing

Test Method

Exome Sequencing with CNV Detection
Test Code Test Copy Genes Gene CPT Codes Copy CPT Codes
NR3C2 81479,81479
SCNN1A 81406,81479
SCNN1B 81406,81479
SCNN1G 81406,81479
Test Code Test Copy Genes Panel CPT Code Gene CPT Codes Copy CPT Code Base Price
10179Genes x (4)81479 81406(x3), 81479(x5) $990 Order Options and Pricing

Pricing Comments

We are happy to accommodate requests for testing single genes in this panel or a subset of these genes. The price will remain the list price. If desired, free reflex testing to remaining genes on panel is available. Alternatively, a single gene or subset of genes can also be ordered via our Custom Panel tool.

An additional 25% charge will be applied to STAT orders. STAT orders are prioritized throughout the testing process.

Click here for costs to reflex to whole PGxome (if original test is on PGxome Sequencing platform).

Click here for costs to reflex to whole PGnome (if original test is on PGnome Sequencing platform).

Turnaround Time

3 weeks on average for standard orders or 2 weeks on average for STAT orders.

Please note: Once the testing process begins, an Estimated Report Date (ERD) range will be displayed in the portal. This is the most accurate prediction of when your report will be complete and may differ from the average TAT published on our website. About 85% of our tests will be reported within or before the ERD range. We will notify you of significant delays or holds which will impact the ERD. Learn more about turnaround times here.

Targeted Testing

For ordering sequencing of targeted known variants, go to our Targeted Variants page.


Genetic Counselors


  • Angela Gruber, PhD

Clinical Features and Genetics

Clinical Features

Pseudohypoaldosteronism type I (PHAI) is a group of disorders characterized by mineralocorticoid resistance in the kidneys and/or other mineralocorticoid target tissues. Patients have high levels of plasma aldosterone and renin, but also develop excessive salt wasting (Tajima et al. 2017. PubMed ID: 28804203). PHAI is classified into three forms. The systemic form results in severe neonatal onset life-threatening salt wasting in multiple organs including sweat glands, salivary glands, the colonic epithelium, and lungs. The renal form is characterized by aldosterone resistance that is restricted to the kidneys. The third form is a type of secondary PHA1 with an unknown mechanism, which is associated with urinary tract infections (UTI) and/or urinary tract malformations.


The systemic form of PHAI is an autosomal recessive disorder that is caused by defects in any one of three genes (SCNN1A, SCNN1B and SCNN1G) (Chang et al. 1996. PubMed ID: 8589714; Hansson et al. 1995. PubMed ID: 7550319). These three genes (each with 12 coding exons) encode the alpha, beta and gamma subunits of the epithelial sodium channel (ENaC), respectively. These amiloride-sensitive channels play a key role in electrolyte transportation across epithelia in many organs.

The renal form of PHAI is an autosomal dominant disorder that is caused by defects in the NR3C2 gene (Geller et al. 1998. PubMed ID: 9662404). The NR3C2 gene (eight coding exons) encodes the mineralocorticoid receptor, which is important in regulating the sodium level in the body.

Genetic defects spread throughout the SCNN1A, SCNN1B, SCNN1G and NR3C2 genes include missense and various truncating variants (nonsense, splicing variants and small deletions/insertions) (Human Gene Mutation Database). Gross deletions and duplications in these genes appear to be rare as only a few large deletions have been documented in SCNN1A, SCNN1B, and NR3C2 to date (Human Gene Mutation Database). Of note, de novo pathogenic variants are common in NR3C2 (Pujo et al. 2007. PubMed ID: 16972228).

Clinical Sensitivity - Sequencing with CNV PGxome

In a multi-center European cohort of Pseudohypoaldosteronism type I (PHAI) patients, pathogenic NR3C2 variants were identified in 87% of kindreds with familial autosomal dominant PHAI and in 81% of patients with a sporadic renal presentation (Pujo et al. 2007. PubMed ID: 16972228).

The diagnostic rate of the systemic form of PHAI by testing the three genes SCNN1A, SCNN1B and SCNN1G in a large cohort of patients is unavailable because studies in the literature only include a limited number of cases.

Gross deletions and duplications in these genes appear to be rare as only a few large deletions have been documented in SCNN1A, SCNN1B, and NR3C2 to date (Human Gene Mutation Database). No large deletions or deletions have yet been found involving SCNN1G.

Testing Strategy

This test is performed using Next-Gen sequencing with additional Sanger sequencing as necessary.

This panel provides 100% coverage of all coding exons of the genes plus 10 bases of flanking noncoding DNA in all available transcripts along with other non-coding regions in which pathogenic variants have been identified at PreventionGenetics or reported elsewhere. We define coverage as ≥20X NGS reads or Sanger sequencing. PGnome panels typically provide slightly increased coverage over the PGxome equivalent. PGnome sequencing panels have the added benefit of additional analysis and reporting of deep intronic regions (where applicable).

Dependent on the sequencing backbone selected for this testing, discounted reflex testing to any other similar backbone-based test is available (i.e., PGxome panel to whole PGxome; PGnome panel to whole PGnome).

Indications for Test

Candidates for this test are patients with pseudohypoaldosteronism type I (PHAI).


Official Gene Symbol OMIM ID
NR3C2 600983
SCNN1A 600228
SCNN1B 600760
SCNN1G 600761
Inheritance Abbreviation
Autosomal Dominant AD
Autosomal Recessive AR
X-Linked XL
Mitochondrial MT

Related Test



  • Chang et al. 1996. PubMed ID: 8589714
  • Geller et al. 1998. PubMed ID: 9662404
  • Hansson et al. 1995. PubMed ID: 7550319
  • Human Gene Mutation Database (Bio-base).
  • Pujo et al. 2007. PubMed ID: 16972228
  • Tajima et al. 2017. PubMed ID: 28804203


Ordering Options

We offer several options when ordering sequencing tests. For more information on these options, see our Ordering Instructions page. To view available options, click on the Order Options button within the test description.

myPrevent - Online Ordering

  • The test can be added to your online orders in the Summary and Pricing section.
  • Once the test has been added log in to myPrevent to fill out an online requisition form.
  • PGnome sequencing panels can be ordered via the myPrevent portal only at this time.

Requisition Form

  • A completed requisition form must accompany all specimens.
  • Billing information along with specimen and shipping instructions are within the requisition form.
  • All testing must be ordered by a qualified healthcare provider.

For Requisition Forms, visit our Forms page

If ordering a Duo or Trio test, the proband and all comparator samples are required to initiate testing. If we do not receive all required samples for the test ordered within 21 days, we will convert the order to the most effective testing strategy with the samples available. Prior authorization and/or billing in place may be impacted by a change in test code.

Specimen Types

Specimen Requirements and Shipping Details

PGxome (Exome) Sequencing Panel

PGnome (Genome) Sequencing Panel

loading Loading... ×


An error has occurred while calculating the price. Please try again or contact us for assistance.

View Ordering Instructions

1) Select Test Method (Platform)

1) Select Test Type

2) Select Additional Test Options

No Additional Test Options are available for this test.

Note: acceptable specimen types are whole blood and DNA from whole blood only.
Total Price: loading
Patient Prompt Pay Price: loading
A patient prompt pay discount is available if payment is made by the patient and received prior to the time of reporting.
Show Patient Prompt Pay Price
Copy Text to Clipboard